The history of the erectile dysfunction drug presents a complex picture for those considering investment. While the initial introduction generated massive gains, the end of its patent opened the floodgates to generic versions, dramatically diminishing sales. This presents a particular challenge for drug manufacturers banking on related blockbuster

The story of Viagra, and its developer copyright, presents a challenging case study for investors. Initially a blockbuster drug, producing billions in revenue , its exclusivity period created a deluge of generic competition , significantly eroding its market share . While some pharmaceutical companies may seek to capitalize on related treatments ,